← Back to Clinical Trials
Recruiting NCT07561840

NCT07561840 Exercise Training After Upper Gastrointestinal Cancer Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07561840
Status Recruiting
Phase
Sponsor Kansai Medical University
Condition Esophageal Cancer
Study Type INTERVENTIONAL
Enrollment 171 participants
Start Date 2026-05-15
Primary Completion 2029-11

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
High-Intensity Interval Training (HIIT)Low-Intensity Continuous Training (LICT)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 171 participants in total. It began in 2026-05-15 with a primary completion date of 2029-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This randomized controlled trial aims to determine the optimal exercise intensity for improving postoperative recovery in patients with upper gastrointestinal cancer. Participants who have undergone curative surgery will be randomly assigned to high-intensity interval training (HIIT), low-intensity continuous training (LICT), or usual care. The exercise interventions will be performed under supervision three times per week for eight weeks. The primary outcome is peak oxygen uptake (VO₂peak), assessed using cardiopulmonary exercise testing. Secondary outcomes include physical function, body composition, patient-reported outcomes, and biological and mechanistic markers such as inflammatory biomarkers, muscle-related factors, and gut microbiota. This study will also explore potential mechanisms underlying exercise-induced adaptations and their association with clinical outcomes.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 18 years * Diagnosed with esophageal or gastric cancer * Received curative surgery * 6 ± 2 weeks after surgery * Ability to provide written informed consent Exclusion Criteria: * Communication difficulties * Poor general status * Undergone combined laryngopharyngectomy * Unsuitable for evaluation or exercise intervention * Unsuitable for the study as determined by the primary physician

Contact & Investigator

Central Contact

Takuya Fukushima

✉ fukushima.tky@kmu.ac.jp

📞 +81-72-856-2115

Principal Investigator

Takuya Fukushima

PRINCIPAL INVESTIGATOR

Kansai Medical University

Frequently Asked Questions

Who can join the NCT07561840 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Esophageal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07561840 currently recruiting?

Yes, NCT07561840 is actively recruiting participants. Contact the research team at fukushima.tky@kmu.ac.jp for enrollment information.

Where is the NCT07561840 trial being conducted?

This trial is being conducted at Hirakata, Japan, Hirakata, Japan.

Who is sponsoring the NCT07561840 clinical trial?

NCT07561840 is sponsored by Kansai Medical University. The principal investigator is Takuya Fukushima at Kansai Medical University. The trial plans to enroll 171 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology